Shots:
- Vir Biotechnology has granted Norgine Pharma, an affiliate of Norgine exclusive commercial rights to the combination of tobevibart & elebsiran for the treatment of chronic hepatitis delta (CHD) in EU, Australia & New Zealand
- As per the deal, Vir will receive ~$64.5M (€ 55M) as initial reimbursement payment & ~ $581.3M (€ 495M) in clinical, regulatory & sales milestones, with tiered, mid-teen to high-twenties% royalties on net sales in Norgine’s licensed territory
- Vir will retain all commercialization rights for the combination in US & other markets outside Greater China, while clinical development costs for the ECLIPSE program will be shared, with Norgine funding about 25% of future external expenses
Ref: PR Newswire | Image: Vir & Norgine | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
